Cholangiocarcinoma Global Market Report 2025

The cholangiocarcinoma market size has grown rapidly in recent years. It will grow from $0.55 billion in 2024 to $0.63 billion in 2025 at a compound annual growth rate (CAGR) of 13.4%. The growth during the historic period can be credited to the increasing incidence of liver and bile duct cancers, rising awareness of rare cancers, a growing focus on personalized treatment, the expansion of immunotherapy approaches, and the rising geriatric population.

The cholangiocarcinoma market size is expected to see rapid growth in the next few years. It will grow to $1.02 billion in 2029 at a compound annual growth rate (CAGR) of 13.1%. The growth during the forecast period can be credited to the increasing adoption of precision medicine, rising healthcare expenditure, the growing prevalence of genetic testing, and the expanding popularity of retail pharmacies. Key trends include advancements in diagnostic techniques, the expansion of clinical trials, the integration of AI in diagnostics, innovations in drug delivery systems, and continued progress in drug development.

The increasing incidence of liver disease is expected to drive the growth of the cholangiocarcinoma market. Liver disease encompasses various conditions that impair the liver's function or structure, including hepatitis, cirrhosis, fatty liver disease, and liver cancer. The rising prevalence of liver disease is attributed to risk factors such as obesity, diabetes, alcohol consumption, and viral hepatitis infections. Chronic inflammation and cirrhosis, in particular, contribute to the development of cholangiocarcinoma by promoting bile duct damage and malignant cell transformation. For instance, in December 2024, the Office for Health Improvement and Disparities, a UK-based government agency, reported that premature deaths from alcoholic liver disease increased by 3.6% in 2023, reaching 5,984 cases compared to 5,776 in 2022. As a result, the rising incidence of liver disease is fueling growth in the cholangiocarcinoma market.

Leading companies in the cholangiocarcinoma market are focusing on innovative treatments, such as targeted therapies, to improve patient outcomes. Targeted therapies are designed to act on specific genes, proteins, or molecules that drive cancer growth. By blocking these processes, targeted therapies can slow tumor progression, minimize side effects, and enhance treatment effectiveness. For instance, in August 2023, Taiho Pharmaceutical Co. Ltd., a Japan-based pharmaceutical company, introduced LYTGOBI (futibatinib), an FGFR inhibitor, for the treatment of unresectable biliary tract cancer with FGFR2 gene fusions. LYTGOBI selectively and irreversibly inhibits FGFR signaling, helping to slow tumor growth and improve patient outcomes in cholangiocarcinoma cases that have progressed after chemotherapy.

In July 2023, Lucence, a US-based precision health company, partnered with Innovent Biologics Inc. to enhance bile duct cancer diagnostics. As part of this collaboration, Innovent sponsored Lucence’s LiquidMARK Bile Duct test for eligible patients in Hong Kong, aiming to improve diagnostic accuracy and expand treatment options. Innovent Biologics Inc. is a China-based biotechnology company specializing in innovative therapies, including treatments for cholangiocarcinoma. This partnership underscores the growing focus on precision diagnostics to enhance early detection and personalized treatment strategies in the cholangiocarcinoma market.

Major players in the cholangiocarcinoma market are F. Hoffmann-La Roche Ltd, Merck & Co. Inc., AbbVie Inc., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Boston Scientific Corporation, Servier Laboratories, Incyte Corporation, Exelixis Inc., Hutchison China MediTech Limited, Zymeworks Inc., Agios Pharmaceuticals Inc., RenovoRx Inc., Specialised Therapeutics Pty Ltd, Ascletis Pharma Inc., Tiziana Life Sciences Ltd., and Taiho Pharmaceutical Co. Ltd.

North America was the largest region in the cholangiocarcinoma market in 2024. The regions covered in cholangiocarcinoma report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the cholangiocarcinoma market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Cholangiocarcinoma is a malignant tumor that develops in the bile ducts, which transport bile from the liver to the small intestine. It is characterized by the uncontrolled growth of abnormal cells, leading to bile duct obstruction and liver dysfunction. Common symptoms include jaundice, abdominal pain, weight loss, and fatigue. Early diagnosis and timely treatment are essential for improving prognosis and disease management.

The primary types of cholangiocarcinoma are intrahepatic and extrahepatic cholangiocarcinoma. Intrahepatic cholangiocarcinoma (ICC) is a rare and aggressive form of liver cancer that originates within the liver's bile ducts. Treatment options vary based on different product types, including capecitabine, 5-fluorouracil, oxaliplatin, gemcitabine, and cisplatin. Available therapies include targeted drug therapy, chemotherapy, and immunotherapy, which are administered through oral, subcutaneous, or intravenous routes. These treatments are distributed through hospital pharmacies, retail pharmacies, and e-commerce platforms.

The cholangiocarcinoma market research report is one of a series of new reports that provides cholangiocarcinoma market statistics, including the cholangiocarcinoma industry global market size, regional shares, competitors with the cholangiocarcinoma market share, detailed cholangiocarcinoma market segments, market trends, and opportunities, and any further data you may need to thrive in the cholangiocarcinoma industry. This cholangiocarcinoma market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The cholangiocarcinoma market consists of revenues earned by entities by providing services such as diagnostic testing and imaging, surgical services, and supportive treatments to manage symptoms and improve patient outcomes. The market value includes the value of related goods sold by the service provider or included within the service offering. The cholangiocarcinoma market also includes sales of advanced imaging systems, molecular diagnostic tests, and drugs. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.